Commentary on Landry et al.: "Propentofylline, a CNS glial modulator, does not decrease pain in post-herpetic neuralgia patients: in vitro evidence for differential responses in human and rodent microglia and macrophages"

Abstract

Landry et al. provide a 2-part study. Part 1 reports the failure of propentofylline to show reduced pain in patients with post-herpetic neuralgia. Part 2 reports cell culture results for macrophages and microglia. Comments regarding each are provided below. Such significant concepts to the field of translational validity of glial cell modulation and related pharmacotherapy as reported in Landry et al. warrant higher standards of study design and data presentation than their paper affords.